Search results
Results from the WOW.Com Content Network
Organ trade (also known as the blood market or the red market) is the trading of human organs, tissues, or other body products, usually for transplantation. [1] [2] According to the World Health Organization (WHO), organ trade is a commercial transplantation where there is a profit, or transplantations that occur outside of national medical systems.
The National Organ Transplant Act (NOTA) of 1984 is an Act of the United States Congress that created the framework for the organ transplant system in the country. [1] The act provided clarity on the property rights of human organs obtained from deceased individuals and established a public-private partnership known as Organ Procurement and Transplantation Network (OPTN).
A sign in Iran saying "I am donating my kidney, Blood type A+" with a telephone number in Persian language. The practice of selling one's kidney for profit in Iran is legal and regulated by the government. In any given year, it is estimated that 1400 Iranians sell one of their kidneys to a recipient who was previously unknown to them. [1]
Within two days an Indian man offered to sell me his kidney. How an ex-Barcelona player's legal liver transplant is focusing attention on the human organ trade Skip to main content
There has been no solid legal foundation supervising organ transplantation since its first practice in Egypt in 1976. [4] Laws prohibited organ donation from the deceased donors, meaning that each organ transplantation practice relies upon one living seller-donor. [13]
(Reuters) -Private equity firm Carlyle Group is in exclusive talks to acquire Baxter International's kidney care spinoff Vantive for more than $4 billion, including debt, a person familiar with ...
Between these regions, there are significant differences in wait time for patients on the organ transplant list. This is of particular concern for liver transplant patients because transplantation is the only cure to end-stage liver disease and without a transplant, these patients will die. [82]
Akkina is one of the researchers involved with a phase 3 trial in organ transplant patients that uses stem cells taken from the organ donor in an attempt to wean the recipients off of these drugs ...